ATE337787T1 - Exemestan zur behandlung von hormonabhängigen störungen - Google Patents
Exemestan zur behandlung von hormonabhängigen störungenInfo
- Publication number
- ATE337787T1 ATE337787T1 AT02727314T AT02727314T ATE337787T1 AT E337787 T1 ATE337787 T1 AT E337787T1 AT 02727314 T AT02727314 T AT 02727314T AT 02727314 T AT02727314 T AT 02727314T AT E337787 T1 ATE337787 T1 AT E337787T1
- Authority
- AT
- Austria
- Prior art keywords
- exemestane
- hormone
- treatment
- dependent disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77091101A | 2001-01-26 | 2001-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE337787T1 true ATE337787T1 (de) | 2006-09-15 |
Family
ID=25090093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02727314T ATE337787T1 (de) | 2001-01-26 | 2002-01-18 | Exemestan zur behandlung von hormonabhängigen störungen |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1377298B1 (de) |
JP (1) | JP2004519490A (de) |
AR (1) | AR032268A1 (de) |
AT (1) | ATE337787T1 (de) |
CA (1) | CA2434611A1 (de) |
DE (1) | DE60214355T2 (de) |
DK (1) | DK1377298T3 (de) |
ES (1) | ES2269682T3 (de) |
MX (1) | MXPA03006607A (de) |
PE (1) | PE20020843A1 (de) |
PT (1) | PT1377298E (de) |
WO (1) | WO2002072106A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
WO2003017973A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method |
GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
US20060173062A1 (en) * | 2003-06-20 | 2006-08-03 | Boice Judith A | Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
JP5256042B2 (ja) * | 2005-11-22 | 2013-08-07 | インサイト・コーポレイション | 癌の処置のための併用療法 |
KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
WO2008019048A1 (en) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Use of aromatase inhibitors for thining the endometrium or treating menorrhagia |
CN101717393A (zh) * | 2009-12-01 | 2010-06-02 | 陈依军 | 环己基2,5-二取代苯基醚的衍生物及其应用 |
DE102010003494A1 (de) * | 2010-03-31 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
EP4249471A3 (de) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmazeutische zusammensetzung von stickstoffhaltige verbindung oder salz davon oder metallkomplex davon |
ES2806276T3 (es) | 2015-12-30 | 2021-02-17 | Univ Saint Louis | Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina |
CN113712974A (zh) * | 2021-08-20 | 2021-11-30 | 南京大学 | 阿司匹林在制备治疗子宫内膜增生药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
GB8617107D0 (en) * | 1986-07-14 | 1986-08-20 | Erba Farmitalia | 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives |
NZ261123A (en) * | 1993-02-18 | 1996-08-27 | Erba Carlo Spa | Fluorinated 4-aminoandrostadienone derivatives |
GB9313420D0 (en) * | 1993-06-29 | 1993-08-11 | Erba Carlo Spa | Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations |
JP2002533416A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法 |
PL360153A1 (en) * | 2000-05-15 | 2004-09-06 | Pharmacia & Upjohn S.P.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
AU8986501A (en) * | 2000-09-08 | 2002-03-22 | Pharmacia & Upjohn Spa | Exemestane as chemopreventing agent |
-
2002
- 2002-01-18 DK DK02727314T patent/DK1377298T3/da active
- 2002-01-18 JP JP2002571065A patent/JP2004519490A/ja not_active Withdrawn
- 2002-01-18 DE DE60214355T patent/DE60214355T2/de not_active Expired - Fee Related
- 2002-01-18 EP EP02727314A patent/EP1377298B1/de not_active Expired - Lifetime
- 2002-01-18 AT AT02727314T patent/ATE337787T1/de not_active IP Right Cessation
- 2002-01-18 MX MXPA03006607A patent/MXPA03006607A/es not_active Application Discontinuation
- 2002-01-18 WO PCT/EP2002/000638 patent/WO2002072106A2/en active IP Right Grant
- 2002-01-18 ES ES02727314T patent/ES2269682T3/es not_active Expired - Lifetime
- 2002-01-18 PT PT02727314T patent/PT1377298E/pt unknown
- 2002-01-18 CA CA002434611A patent/CA2434611A1/en not_active Abandoned
- 2002-01-23 PE PE2002000050A patent/PE20020843A1/es not_active Application Discontinuation
- 2002-01-24 AR ARP020100236A patent/AR032268A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1377298A2 (de) | 2004-01-07 |
PE20020843A1 (es) | 2002-09-25 |
PT1377298E (pt) | 2006-12-29 |
CA2434611A1 (en) | 2002-09-19 |
WO2002072106A3 (en) | 2003-10-30 |
AR032268A1 (es) | 2003-10-29 |
EP1377298B1 (de) | 2006-08-30 |
MXPA03006607A (es) | 2003-09-22 |
ES2269682T3 (es) | 2007-04-01 |
JP2004519490A (ja) | 2004-07-02 |
WO2002072106A2 (en) | 2002-09-19 |
DE60214355D1 (de) | 2006-10-12 |
DK1377298T3 (da) | 2007-01-02 |
DE60214355T2 (de) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
ATE451921T1 (de) | Phenylindole zur behandlung von hiv | |
DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
ATE247117T1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
ATE293610T1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE376444T1 (de) | Ibandronsäure zur behandlung und vorbeugung von osteoporose | |
DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
ATE293447T1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60218451D1 (de) | 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation | |
DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE60233186D1 (de) | Verbessertes System zur Behandlung von Elementarschwefel-Rückständen | |
ATE337787T1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
ATE254913T1 (de) | Diacerein zur behandlung von psoriasis | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
DE60021252D1 (de) | Antikonvulsiva zur behandlung von autismus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1377298 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |